Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Concert Pharmaceuticals, Inc is a biotechnology business based in the US. Concert Pharmaceuticals shares (CNCE) are listed on the NASDAQ and all prices are listed in US Dollars. Concert Pharmaceuticals employs 70 staff and has a trailing 12-month revenue of around USD$7.9 million.
|Latest market close||USD$11.33|
|52-week range||USD$5.47 - USD$13.4|
|50-day moving average||USD$11.4849|
|200-day moving average||USD$10.5179|
|Wall St. target price||USD$24|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.347|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-12)||-8.85%|
|1 month (2020-12-18)||-7.21%|
|3 months (2020-10-20)||-1.73%|
|6 months (2020-07-17)||9.47%|
|1 year (2020-01-17)||8.73%|
|2 years (2019-01-18)||-20.32%|
|3 years (2018-01-19)||19.61|
|5 years (2016-01-19)||14.94|
|Revenue TTM||USD$7.9 million|
|Gross profit TTM||USD$-58,739,000|
|Return on assets TTM||-29.52%|
|Return on equity TTM||-58.95%|
|Market capitalisation||USD$380.1 million|
TTM: trailing 12 months
There are currently 798,014 Concert Pharmaceuticals shares held short by investors – that's known as Concert Pharmaceuticals's "short interest". This figure is 3.8% up from 768,999 last month.
There are a few different ways that this level of interest in shorting Concert Pharmaceuticals shares can be evaluated.
Concert Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Concert Pharmaceuticals shares currently shorted divided by the average quantity of Concert Pharmaceuticals shares traded daily (recently around 173104.98915401). Concert Pharmaceuticals's SIR currently stands at 4.61. In other words for every 100,000 Concert Pharmaceuticals shares traded daily on the market, roughly 4610 shares are currently held short.
However Concert Pharmaceuticals's short interest can also be evaluated against the total number of Concert Pharmaceuticals shares, or, against the total number of tradable Concert Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Concert Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Concert Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.0255% of the tradable shares (for every 100,000 tradable Concert Pharmaceuticals shares, roughly 26 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Concert Pharmaceuticals.
Find out more about how you can short Concert Pharmaceuticals stock.
We're not expecting Concert Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Concert Pharmaceuticals's shares have ranged in value from as little as $5.47 up to $13.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Concert Pharmaceuticals's is 0.7869. This would suggest that Concert Pharmaceuticals's shares are less volatile than average (for this exchange).
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for the treatment of autoimmune and central nervous system disorders. Its product candidates include CTP-543, which is in Phase III clinical trials for the treatment of alopecia areata; CTP-692, a selective deuterium-modified analog of the endogenous amino acid and D-serine that is in Phase II trials for the treatment of schizophrenia; and AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease. The company has strategic collaborations with Avanir Pharmaceuticals, Inc.; Cipla Technologies; Processa Pharmaceuticals; and Jazz Pharmaceuticals, Inc. Concert Pharmaceuticals was founded in 2006 and is headquartered in Lexington, Massachusetts.
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.